CHRISTOPHER JOHN KENNEY - 11 Mar 2024 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
Chief Medical Officer
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
11 Mar 2024
Net transactions value
$0
Form type
4
Filing time
12 Mar 2024, 18:38:34 UTC
Previous filing
24 Mar 2023
Next filing
13 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 11 Mar 2024 Common Shares 100,000 $44.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.